HC Wainwright & Co. Downgrades Intercept Pharma to Neutral, Announces $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has downgraded Intercept Pharma (NASDAQ:ICPT) from Buy to Neutral and set a price target of $19.
September 27, 2023 | 10:44 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intercept Pharma has been downgraded from Buy to Neutral by HC Wainwright & Co. with a new price target of $19.
The downgrade from Buy to Neutral by a prominent analyst indicates a less optimistic outlook for the company's stock. This could potentially lead to a decrease in the stock's price in the short term. The new price target of $19 also suggests a potential downside from the current price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100